Astellas Targets Generic Versions Of Bladder Drug Myrbetriq
Astellas Pharma Inc. on Thursday filed three lawsuits in Delaware federal court seeking to block generic versions of its patent-protected overactive bladder treatment Myrbetriq, which were proposed by Aurobindo Pharma, Windlas...To view the full article, register now.
Already a subscriber? Click here to view full article